$0.62
1.10% today
Nasdaq, Feb 28, 04:51 pm CET
ISIN
US67577C1053
Symbol
OCGN
Sector
Industry

Ocugen Inc Stock price

$0.61
-0.12 16.54% 1M
-0.72 54.12% 6M
-0.19 24.20% YTD
-0.38 38.36% 1Y
-2.91 82.66% 3Y
+0.20 48.36% 5Y
-639.59 99.90% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.00 0.02%
ISIN
US67577C1053
Symbol
OCGN
Sector
Industry

Key metrics

Market capitalization $177.54m
Enterprise Value $145.62m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 30.98
P/S ratio (TTM) P/S ratio 37.77
P/B ratio (TTM) P/B ratio 4.36
Revenue (TTM) Revenue $4.70m
EBIT (operating result TTM) EBIT $-52.44m
Free Cash Flow (TTM) Free Cash Flow $-49.17m
Cash position $38.70m
EPS (TTM) EPS $-0.18
P/E forward negative
P/S forward 49.01
EV/Sales forward 40.20
Short interest 20.58%
Show more

Is Ocugen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Ocugen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Ocugen Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Ocugen Inc forecast:

Buy
100%

Financial data from Ocugen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
4.70 4.70
-
100%
- Direct Costs 1.55 1.55
42% 42%
33%
3.15 3.15
389% 389%
67%
- Selling and Administrative Expenses 23 23
28% 28%
481%
- Research and Development Expense 31 31
34% 34%
669%
-51 -51
36% 36%
-1,083%
- Depreciation and Amortization 1.55 1.55
42% 42%
33%
EBIT (Operating Income) EBIT -52 -52
35% 35%
-1,116%
Net Profit -51 -51
32% 32%
-1,088%

In millions USD.

Don't miss a Thing! We will send you all news about Ocugen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocugen Inc Stock News

Neutral
GlobeNewsWire
one day ago
MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that alignment has been reached with the U.S. Food and Drug Administration (FDA) to move forward with a Phase 2/3 pivotal confirmatory clinical trial for OCU410ST which, if positive, can be the basis of a...
Neutral
GlobeNewsWire
7 days ago
MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2024 financial results and provide a ...
Neutral
GlobeNewsWire
16 days ago
MALVERN, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that dosing is complete, ahead of schedule in the Phase 2 portion of the Phase 1/2 ArMaDa clinical trial for OCU410—a novel multifunctional ...
More Ocugen Inc News

Company Profile

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline includes OCU400, OCU410, OCU200, OCU200, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.

Head office United States
CEO Shankar Musunuri
Employees 65
Founded 2013
Website www.ocugen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today